Meta-Analysis of Tocilizumab Biosimilars: Efficacy, Safety, and Pharmacokinetics

A systematic review and meta-analysis of eight randomized controlled trials evaluating tocilizumab biosimilars against the reference drug. The dataset includes results from 3,059 total participants, comprising 1,696 rheumatoid arthritis patients and 1,363 healthy volunteers. The analysis was registered in PROSPERO and published on figshare under a CC-BY-4.0 license.

Use Cases

• Compare efficacy outcomes based on DAS28-ESR and ACR20/50/70 response rates between biosimilar and reference drugs.
• Assess safety profiles based on adverse event and serious adverse event rates reported in the included trials.
• Evaluate pharmacokinetic biosimilarity based on AUC and Cmax parameters from phase I studies.
• Analyze immunogenicity risk based on anti-drug antibody positivity rates.

Strengths

• Analysis is based on 8 randomized controlled trials, providing a structured evidence base.
• Includes data from 3,059 total participants, split between patient and healthy volunteer cohorts.
• Reports specific statistical outcomes (e.g., mean differences, risk ratios, geometric mean ratios) with confidence intervals.

Limitations

• The underlying data file is a DOCX document (357.0 KB); structured tabular data is not directly available.
• Row count and column-level documentation are unknown, limiting suitability assessment for direct computational analysis.
• Data may reflect the publication bias inherent to meta-analyses of published clinical trials.

Provenance

Source

figshare admin karger

Collection Method

Systematic literature review and meta-analysis of trials from PubMed, Embase, and Cochrane CENTRAL.

Freshness

Last updated 2026-05-07 09:55:11; freshness should be verified.